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Prostate cancer (PCa) is estimated to be the second leading cause of cancer-
related deaths among men in the United States in 2019. While most prostate tumors 
rely on androgens for growth signaling, there are subsets of tumors that become 
androgen-resistant. For these tumors, known as castration-resistant PCa, the 
conventional treatment of androgen-deprivation therapy fails and the cancer cells 
continue to proliferate despite low levels of androgens in the body. Consequently, 
research has focused on targeting different hormone receptors for novel therapeutics. 
The most common hormone receptors being researched are ERα and ERβ. However, 
their roles within PCa are complicated and have not been fully elucidated. Another 
lesser-known hormone receptor that is being researched is Dosage-sensitive sex 
reversal, adrenal hypoplasia critical region, on chromosome X, gene 1 (DAX-1). DAX-1 
is known to interact with other hormone receptors, such as androgen receptor (AR) and 
estrogen receptor (ER), and suppress the proliferative effects of their signaling. 
Previous research has shown DAX-1 binds to AR in PCa cell lines, but little work has 
been done on the association of ER and DAX-1 in these cell lines. Therefore, the aim of 
this project was to explore DAX-1 and ER binding in the context of PCa cell lines. 
We utilized two different PCa cell lines, an androgen-dependent line and an 
androgen-resistant line, and analyzed gene and protein expression of DAX-1, ERα, and 
ERβ. Both cell lines were found to express the proteins of interest at varying degrees. 
We also used immunofluorescence microscopy to detect the protein localization and 
found DAX-1 and ERα as well as DAX-1 and ERβ co-localize in PCa cell lines, 
regardless of the androgen response of the cell line. This novel finding suggests that the 
hormone receptors bind in vivo in PCa cell lines. GST pull-down assays along with co-
immunoprecipitation assays were then performed to assess bona fide interaction of 
DAX-1 and ERα.  Although the results from these assays were inconclusive, our 
previous results of hormone receptor co-localization support the idea that DAX-1 does 
bind ERs in vivo. These results strongly suggest DAX-1 utilizes both ER and AR as 
binding partners in PCa cells and mediates its anti-proliferative effects in prostate 
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Introduction to Prostate Cancer and Nuclear Hormone Receptors 
 
Prostate cancer 
Prostate cancer (PCa) is estimated to be the most diagnosed cancer in men in 
the United States in 2019. Approximately, one in five new male cancer diagnoses will be 
prostate cancer, totaling 174,650 new cases. PCa is also estimated to be the second 
most deadly cancer in men in the United States accounting for 10% of total male cancer 
deaths [1]. The median age of patients diagnosed with PCa is 66 years old [2]. Men 
have an increased risk in developing high-risk PCa as a result of age [3-4]. Race also 
plays a large factor in predicting which men will be diagnosed with PCa. Those of 
African-American descent have the highest chance of being diagnosed with PCa, with 
one in seven non-Hispanic black men being diagnosed with PCa over a lifetime 
compared to one in eight non-Hispanic white men [5]. Black men are also twice as likely 
to die from PCa than white men [5]. Additional risk factors associated with PCa are 
family genetics, mutations in the BRCA1 and BRCA2 genes, and lifestyle factors such 
as smoking [6-10] 
Like most cancers, PCa is diagnosed and evaluated through numerous 
techniques. The initial test is a digital rectal exam performed by a physician followed by 
testing the level of prostate-specific antigen (PSA) in the blood. Healthy prostate cells 
secrete PSA in low numbers and over time, the cells gradually secrete an increasing 
amount of PSA. However, a rapid increase in an individual’s PSA levels compared to a 
baseline level (usually determined in the patient’s early 40s) indicates either the 
prostate has enlarged or prostate cells are dividing rapidly and uncontrollably indicating 
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a cancerous phenotype [11]. If PSA levels are elevated, a biopsy of the tissue is taken 
and the tissue is given a Gleason score and a stage. The Gleason score determines 
whether the PCa looks like healthy tissue when viewed under a microscope. The higher 
the Gleason score, the more the cancer cells look undifferentiated [11-12] and the 
higher the likelihood the cancer will grow more rapidly. However, Gleason score alone 
cannot determine whether a patient is likely to have an aggressive form of PCa. Staging 
is another technique that involves evaluating the tumor based on the Tumor, Node, 
Metastasis (TNM) system. The TNM system evaluates the primary tumor location and 
size, whether the PCa has spread to the lymph nodes, and whether the PCa has 
metastasized to another tissue. Based on these categories, patients are given a stage 
ranging from 0 to IV, with stage 0 meaning no evidence of PCa was found within the 
patient and stage IV meaning the PCa has metastasized beyond the prostate [13]. 
Treatment for PCa depends on the Gleason score combined with the cancer stage. The 
higher the Gleason score and the higher the stage, the more aggressive the PCa 
treatment for the patient. 
Prostate cancers primarily rely on androgens to stimulate proliferative and 
survival genes via androgen receptor (AR), a type of nuclear hormone receptor [14]. 
Therefore, the typical course of treatment of PCa relies on androgen-deprivation 
therapy (ADT), also known as androgen ablation therapy. This form of treatment 
involves either surgical castration, known as orchiectomy, or medical castration that 
manipulates levels of luteinizing-hormone release-hormone (LHRH) in the 
hypothalamus to considerably reduce the amount of testosterone produced by the 
testes [15]. Randomized clinical trials have exhibited the benefits of ADT, including 
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long-term survival, disease progression, and local control, in both intermediate-risk PCa 
and high-risk PCa [16-17]. Additionally, multiple randomized clinical trials have 
demonstrated the benefits of adjuvant use of radiation therapy along with ADT. The 
results found that the addition of radiation therapy to ADT allowed for a longer five-year 
survival rate compared to ADT or radiation therapy alone [18-20]. 
The Nuclear Hormone Receptor Family and Estrogen Receptor 
While there has been significant improvement in therapies over the years, PCa 
that has metastasized beyond the sex organs primarily into bone and lungs has a poor 
five-year survival rate of 30% [1]. These PCa cells become androgen-resistant and 
continue to proliferate despite low levels of testosterone in the body. These tumors are 
known as castration-resistant prostate cancer (CRPC) and are virtually impossible to 
cure with current treatments [21-22]. For this reason, scientists are looking into novel 
treatments for CRPC. One avenue of CRPC treatment researchers are exploring is 
targeting other nuclear hormone receptors (NHRs) for hormone therapies that would 
impact PCa proliferation and metastasis.  
NHRs are a unique family of ligand-inducible transcription factors that regulate 
gene expression [23-24]. Typical members of this family have 6 conserved regions 
(distinguished as regions A-F), each having a different function. Regions A/B comprise  
the variable N-terminal domain that is important in gene regulation and includes the 
ligand-independent transactivation domain, called activation function 1 (AF1) [25-26].  
Region C contains the highly conserved DNA binding domain (DBD). The DBD contains 
two zinc finger motifs allowing the receptor to “read” the DNA and find the appropriate 
five to six base pair start of the DNA response element (RE) in the promoter of the 
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regulated gene. DNA response elements allow transcription factors to bind DNA 
upstream from their gene targets, essentially allowing transcription factors to recognize 
their correct targets [27-28]. Region D acts as the hinge region and is a link to the 
conserved region E. The variable hinge region of the receptor contains a nuclear 
localization signal and assists with DNA recognition [24; 29-31]. Regions E and F 
contain the ligand binding domain (LBD) along with the variable C-terminus of the 
protein[24]. The LBD is composed of 12 alpha-helices that mediate ligand binding and 
also assist in co-receptor binding as well as homo- or heterodimerization of receptors 
[32-33]. The ligand-dependent activation function 2 (AF2) is also included within this 
region. Depending on the nature of the ligand, NHRs can be further classified into 
steroid hormone receptors such as androgen receptor and estrogen receptors (ER), 
non-steroid hormone receptors such as those that respond to vitamin D or retinoids, and 
orphan receptors with no known ligands [34-37]. In total, there have been 48 NHRs 
identified to date, with each category of NHR having a slightly different mechanism of 
action.  
The typical mechanism of a steroid hormone receptor starts with the ligand 
diffusing across the plasma membrane of the cell. Once inside the cell, the ligand binds 
to its respective receptor located in the cytoplasm, which causes the receptor to be 
released from an anchoring protein. Homo- or heterodimerization of the ligand-receptor 
complex occurs and coactivators are recruited to these complexes. The overall ligand-
receptor-coactivator complex enters the nucleus where it uses the NHR’s DBD to bind 







Figure 1-1. The typical mechanism of action of a steroid hormone NHR. The ligand crosses 
the plasma membrane of the cell where it binds to its respective NHR. The binding of the ligand 
causes the anchoring HSP (heat shock protein) to release the NHR. Two activated NHRs can 
homodimerize and recruit coactivators to the complex. The whole complex translocates to the 




NHRs play an important role in prostate cancer, with AR acting as the main driver 
of PCa and therefore being the most studied NHR within this cancer. However, some 
studies have explored the role of ER within PCa. Estrogen receptors are NHRs that 
respond to estrogens as ligands. There are two distinct genes that code for ER proteins, 
with the two most common isoforms being ERα and ERβ1. The ESR1 gene codes for 
ERα while the ESR2 gene codes for ERβ1. Both ERs are typical NHRs and contain an 
N-terminal DBD and ligand-independent AF-1 domain along with the C-terminal LBD 
and ligand-dependent AF2 domain. The isoforms have high sequence homology except 
in their LBDs, suggesting that different estrogens preferentially bind ERα or ERβ1 
(Figure 1-2). Indeed, ERα demonstrates a higher affinity for estradiol (E2) while ERβ1 
has a higher affinity for 3β-Androstanediol, an estrogen that is a metabolite of androgen 
conversion [38]. 
Historically, clinical studies have looked at the effect of the oral estrogen, 
diethylstilbesterol, on prostate tumors [39-41]. These efforts were deemed unfavorable 
when the studies noted the orally administered estrogens did not improve the overall 
survival of the patients yet the level of cardiovascular toxicity was highly increased [42-
43]. While these studies are quite old, more recent efforts are being made to study the 
effect of parenteral and dermal estrogen therapy on thromboembolic effects and bone 
mineral density in PCa patients [43-44].  
Laboratory-based studies have explored the roles of ERα and ERβ in the context 
of PCa. ERα is thought to behave as oncogene as activation of ERα via E2 binding 
mediates proliferation signals and prostatic carcinogenesis. Adding to the evidence that 
ERα is oncogenic, mice ERα knockout models do not develop PCa after treatment with 
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estrogen or testosterone, indicating ERα is necessary for PCa progression [45]. In 
contrast ERβ, which tends to be down-regulated as PCa progresses, seems to act in a 
non-oncogenic manner as ERβ agonists have slowed the proliferation of prostatic 
epithelium cells [46]. ERβ activation lead to apoptosis in the CRPC cell lines DU145 and 
PC3 [47]. These findings indicate ERα and ERβ have larger roles in PCa than 
previously thought. However, studies are needed to further explore the role of estrogen 
receptors and other NHRs in the progression of PCa tumors, specifically in the 










Figure 1-2. Schematic of Estrogen Receptor Alpha and Beta proteins. The two ER 
proteins are coded by different genes, ESR1 and ESR2. ESR1 codes for ERα and is located 
on chromosome 6 while ERβ is coded by ESR2 which is located on chromosome 14. ERα and 
ERβ are typical NHRs with an AF1 region and DBD region in the N-terminus and LBD and AF2 
regions in the C-terminus. The proteins share a high level of homology in their DBD domains 
but only a 55% sequence homology in their LBD domains. This suggests that each ER 
preferentially binds different estrogen ligands.  
Vijayraghavan, Meghana 
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DAX-1: an unusual NHR 
One such NHR is the orphan receptor DAX-1, encoded by the NR0B1 gene. 
DAX-1 is known as an orphan receptor since it has no known ligand. The protein plays 
an important role in mammalian steroidogenesis, reproduction, and sex development 
[48-52]. Originally, the NR0B1 gene was found to be associated with two disorders.  
Adrenal hypoplasia congenita (AHC) in which the adrenal glands fail to develop properly 
and hypogonadotropic hypogonadism (HH) in which DAX-1 is over-expressed resulting 
in male-to-female sex reversal. Because of its association with these two disorders, the 
protein’s name stands for Dosage sensitive sex reversal, Adrenal hypoplasia congenita 
critical region on chromosome X, gene 1 [53]. The gene is expressed in tissues highly 
influenced by hormones such as the developing adrenal gland, pituitary gland, 
hypothalamus, and gonads [54]. The DAX-1 protein is unusual as it lacks several 
conserved functional domains typical of other NHRs. Specifically, instead of having an 
N-terminal domain containing an AF-1, DBD, and hinge region, DAX-1 contains three 
full-length alanine/glycine-rich repeat domains and one half-length domain. These 
repeats harbor short leucine motifs known as LXXLL motifs that are commonly seen in 
nuclear receptor coactivators and corepressors [53; 55-56] (Figure 1-3). Because of 
these leucine-rich motifs, DAX-1 has been studied in the context of other nuclear 
hormone receptors. It has been shown to act as a transcriptional corepressor of other 
nuclear hormone receptors including steroidogenic factor 1, estrogen receptor, 
androgen receptor, progesterone receptor, and liver receptor homologue 1 [57-63]. It is 
proposed that DAX-1 binds to the coactivator-binding surface in the LBD of other NHRs 
using its LXXLL motifs, specifically the leucine amino acids, found in its N-terminus. By 
Vijayraghavan, Meghana 
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binding to the coactivator-binding surface, DAX-1 is able to competitively inhibit NHR 









Figure 1-3. Schematic of DAX-1 protein. DAX-1, encoded by the NR0B1 gene, is an 
unusual, orphan NHR. The protein differs from typical NHRs by not housing a DBD region, AF1 
region, or hinge region within its N-terminus. Instead the protein exhibits 3.5 leucine-rich 
LXXLL motifs which help the protein bind to typical NHRs in their LBDs. Though DAX-1 
maintains LBD and AF2 regions in its C-terminus, no known ligand has been elucidated for this 
NHR, making it an orphan. 
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In light of DAX-1’s role in transcriptional regulation, studies have shifted to focus 
on its possible role in various tumors. Adrenocortical neoplasms were the first type of 
tumors to be analyzed for DAX-1 expression [64]. One study proposed that higher DAX-
1 expression in adrenocortical tumors limits steroidogenic factor 1 transcriptional activity 
thereby resulting in reduced cell proliferation and tumor formation [65]. Additional 
studies have correlated DAX-1 to clinical parameters in different types of human tumors 
suggesting the altered expression of DAX-1 could act as a clinical marker for certain 
cancers. It is worth noting the differing antibodies and IHC techniques used in these 
studies make for variable interpretation of the results.  In lung adenocarcinomas, high 
DAX-1 expression was associated with lymph node metastasis [66]. Conversely, in 
breast cancer and endometrial carcinomas, DAX-1 immunoreactivity was inversely 
correlated with nodal status and histological grade, respectively [67-68]. Similarly, in 
prostate cancer DAX-1 immunoreactivity correlated inversely with tumor Gleason 
scores. However, the study found no correlation between the status of DAX-1 and the 
status of the NHRs tested including ERβ and AR in patient samples [69]. This is an 
interesting discrepancy since previous work has demonstrated the ability of DAX-1 to 
act as a corepressor of ERs in vitro and in vivo using COS-7 cells that are fibroblast-like 
cells derived from primate kidney tissue [60]. COS-7 cells are mainly used since they 
are mammalian cells, widely available, and easy to transfect. However, in the context of 
human prostate cancer cells, both hormone-naïve and CRPC cells, there are no 
published studies to date that explore the relationship between DAX-1 and ERs. If an 
association is found between the NHRs, the ER-DAX-1 heterodimer could be further 
studied as a possible target for novel prostate cancer therapeutics. 
Vijayraghavan, Meghana 
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We hypothesize that DAX-1 binds ER within prostate cancer cell lines and this 
binding serves to act as a transcriptional repressor of proliferative and metastatic genes. 
The first aim of this study was to determine whether DAX-1 and both isoforms of ER 
were endogenous to both hormone-naïve and CRPC cell lines. PCR, immunoblotting, 
and immunofluorescence microscopy suggested that all three NHRs were present in 
both types of PCa cell lines, with DAX-1 being mostly localized to the nuclei of the cells 
and ER being diffused among the cytoplasm and the nuclei of the cells. The next aim of 
this study was to determine if DAX-1 binds to ER within the PCa cell lines. GST pull-
down assays along with co-immunoprecpitation assays were used to evaluate the 
protein-protein interaction both in vitro and in vivo. The results from this portion of the 
study were inconclusive and future work needs to be carried out to confirm this 
interaction exists and if so, to determine the strength and context of the interaction. 
Elucidating the mechanisms of DAX-1 and ER within PCa cell lines will allow new target 





DAX-1 and ER expression in prostate cancer cell lines 
Introduction 
As described in Chapter 1, androgen deprivation therapy (ADT) is the main form 
of treatment for PCa. However, ADT eventually fails leaving few other options for cancer 
treatment. The need for other forms of hormonal and NHR-mediated treatments are 
glaring when ADT fails.  
While the status of ERα and ERβ within PCa has been reported in many studies, 
the results are conflicting due to the variation of PCa models used (mice models, cell 
lines, etc.) and the variety of techniques employed. ERα is mainly expressed in stromal 
cells of healthy prostate tissue, though it has been found in basal-epithelial cells 
occasionally. ERβ is primarily localized to the basal-epithelial cells within the prostate 
[70-72]. Crosstalk between the two compartments, the stroma and the epithelium, plays 
an important role in the progression of prostate carcinogenesis as reviewed by Niu and 
Xia [73]. Therefore, the differential expression of ERs within these compartments 
indicate ERα and ERβ have different roles in healthy prostate tissue and likely have 
differing roles within PCa tissues. Within PCa cell models and tissue samples, ERα is 
considered to be an oncogene that is highly expressed in epithelial tissues, as opposed 
to its stromal expression in healthy prostate tissue. ERα mediates proliferation, 
inflammation, and prostate carcinogenesis. ERα knockout mice that were treated with 
testosterone and estrogen did not develop prostate carcinomas indicating that within 
PCa mice models, ERα is a necessary component to induce prostate carcinogenesis 
[45]. Additionally, ERα, but not ERβ, is highly up-regulated in the prostate of transgenic 
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mice models which closely mimics the pathogenesis of human PCa compared to wild-
type models, suggesting once again, ERα is the predominant ER mediating prostate 
carcinogenesis in mice models [74]. Within human samples, ERα is repeatedly detected 
in tissues from patients with higher Gleason scores and poor survival rates [75-76]. 
In contrast to the widely accepted oncogenic effects of ERα, ERβ has a more 
controversial role within PCa. Generally, it is thought that ERβ acts in opposition to ERα 
and has anti-proliferative, pro-apoptotic effects within PCa. In ERβ knockout mice, the 
absence of ERβ compared to wild-type mice resulted in an increase in proliferation of 
epithelial cells, a decrease in apoptotic cells, and an increase in undifferentiated cells 
[77-78]. When stimulated with 3β-androstanediol, a ligand that only activates the ERβ 
receptor, wild-type mice had reduced AR expression levels in comparison to the ERβ 
knockout mice. The reduction of AR levels suggests ERβ potentially regulates AR 
expression. Since AR is known to be a driver of PCa progression, it would be 
worthwhile to look into ERβ-specific treatments for hormonal therapies. In human 
cancer models, ERβ is down-regulated as the PCa progresses suggesting that the NHR 
is needed to maintain a lower grade phenotype [79]. ERβ activation and up-regulation in 
CPRC cell lines inhibited cell proliferation and cell invasiveness while triggering 
apoptosis [47; 80-81]. However, the anti-proliferative effects of ERβ have been disputed 
within PCa cell line models. When stimulated with estradiol (E2) and an ERβ-selective 
agonist, diarylpropionitrile, both a normal human prostate cell line and a CRPC cell line 
exhibited an increase in DNA synthesis, an increase in the cyclin D2 protein that 
mediates the cell cycle, and an increase in proliferation [82]. These findings are in direct 
contrast to the proposed role of ERβ within PCa progression, highlighting the fact that 
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more studies need to be performed to elucidate the location and the roles of ERs within 
PCa models. 
Another NHR of particular interest to our lab is DAX-1. As mentioned in Chapter 
1, expression of DAX-1 in cancerous steroidogenic tissues has been correlated to better 
grades or statuses of those cancers. Though these studies are only correlative, they 
point to an unknown role that DAX-1 plays in these cancers. DAX-1 has been detected 
in both cancerous and non-cancerous prostatic tissues and is reportedly strongly 
expressed in normal prostate epithelial cells but is absent in the CRPC cell line, PC3 
[62; 83]. However, DAX-1 exhibited a variable detection pattern in patient PCa tissues 
with expression inversely correlating to Gleason score [69]. The variable pattern was 
unexpected given that DAX-1 expression seems to decrease as PCa progresses. 
Further studies are required in order to clarify the ill-defined expression pattern of DAX-
1 within cancerous prostatic tissues. 
Therefore, the objective of this portion of the thesis work was to investigate the 
expression and localization of endogenous DAX-1 protein in a hormone-naïve and a 
CRPC cell line. ERα and ERβ expression and localization was also assessed in these 
cell lines and co-localization of the ERs with DAX-1 was explored. Furthermore, DAX-1 
was overexpressed using adenovirus-based delivery methods in order to assess 




Materials and Methods 
Cell Culture 
LNCaP and PC3 cell lines were obtained from ATCC (American Type Culture 
Collection; Manassas, VA). The cell lines were grown in complete media consisting of 
Roswell Park Memorial Institute (RPMI) 1640 medium (Thermo Fisher Scientific; 
Waltham, MA) supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher 
Scientific), 1% Penicillin-Streptomycin antibiotic solution (Invitrogen; Carlsbad, CA), 1% 
HEPES buffer (Mediatech Inc; Manassas, VA), 1% sodium pyruvate (Thermo Fisher 
Scientific), 1% glucose (Mediatech Inc), and 0.2% sodium bicarbonate (Mediatech Inc.). 
Cells were incubated at 37°C with 5% CO2 in a humidified chamber. Cells were sub-
cultured at least twice a week using 0.25% Trypsin-EDTA (Thermo Fisher Scientific) as 
per their respective ATCC guidelines, with a 1:3-1:6 split ratio.  
LNCaP cells were originally isolated from a 50 year old Caucasian male in 1977. 
These cells are hormone naïve. PC-3 cells were derived from a bone metastasis of a 
grade IV adenocarcinoma in a 62 year-old Caucasian male in 1979. The cells are 
representative of advance PCa. They do not respond to androgens nor do they express 
DAX-1. PC-3 cells have high metastatic potential compared to other prostate cancer 
cells.  
Adenovirus transduction   
Recombinant human DAX-1 adenovirus was obtained from Creative Biogene 
Biotechnology (Shirley, NY) at a concentration of 2.62 x 108 vp/mL. DAX-1 adenovirus 
inoculum was prepared using 1 μL of virus per 1 mL of complete media. LacZ 
adenovirus inoculum was prepared by adding CMV LacZ adenovirus (Applied Biological 
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Materials Inc.; Richmond, BC, Canada) at the same concentration as the DAX-1 viral 
inoculum.  
 LNCaP cells, or alternatively, PC3 cells were seeded into 6-well dishes in 
duplicates at varying densities depending on the assay. Cells were incubated in 
complete media overnight (12-16 hours) in a humidified chamber at 37°C with 5% CO2. 
The next day, the cells were checked for confluence of at least 40% prior to infection. 
Viral inoculum was prepared according to the protocol above. Old media was gently 
aspirated and the viral inoculum was added for a total of 2 mL/well. Cells were seeded 
in duplicates and were either untreated, treated with LacZ adenovirus, or treated with 
DAX-1 adenovirus. The cells were incubated with the virus in a humidified chamber at 
37°C with 5% CO2 for 48-72 hours, depending on the assay being performed. After 
incubation, cells were harvested and either RNA or protein lysate were collected. 
RNA extraction  
Following a 48 hours infection with no treatment, LacZ adenovirus, or DAX-1 
adenovirus, cells were harvested and RNA isolated according to the manufacturer’s 
instructions using the Qiagen RNeasy Midi Prep Kit (Qiagen; Hilden, Germany). The 
collected RNA was quantified using the ND-1000 Nanodrop (Thermo Fisher Scientific). 
RNA was immediately used for cDNA synthesis and the remaining RNA was stored at -
20°C. 
cDNA synthesis 
A calculated amount of RNA (1000 ng) was reversed transcribed into cDNA 
using the Quantabio qScript cDNA Supermix kit (Quantabio; Beverly, MA) according to 
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the manufacturer’s instructions. cDNA was either immediately used for PCR reactions 
or stored at -20°C until use. 
 
Reverse-transcription polymerase chain reaction  
Synthesized cDNA was amplified via polymerase chain reaction (PCR) and used 
to detect expression of the NR0B1 (DAX-1), ESR1 (ERα), and ESR2 (ERβ) genes. 
GAPDH was used as a housekeeping gene and loading control. GAPDH 
(glyceraldehyde 3-phosphate dehydrogenase) is a gene that encodes the GAPDH 
enzyme that is critical for glycolysis to occur. This gene remains constant in the cells 
and is unlikely to change when DAX-1 is up-regulated. The forward and reverse primers 
for each gene are detailed below (Table 2-1). Each PCR reaction was assembled for a 
final volume of 20 μL using 10 μL GoTaq Green Master Mix (Promega; Madison, WI), 1 
μL of 10 μM forward and reverse primers, 1 μL cDNA, and 8 μL of nuclease free dH2O. 
The PCR reactions were performed using the Bio-Rad C1000 Touch Thermal cycler 
(Bio-Rad; Hercules, CA) following the protocol described in Table 2-2. PCR products 
were resolved in a 2% agarose gel and imaged using the Bio-Rad ChemiDoc XRS+ 









 Table 2-1. Forward and Reverse primer sequences for genes of interest 
Gene of 
Interest 




NR0BI GACTCCAGTGGGGAACTCAG  ATGATGGGCCTGAAGAACAG  154 bp 
ESR1 GACAGGGAGCTGGTTCACAT AGGATCTCTAGCCAGGCACA 110 bp 
ESR2 TGAAAAGGAAGGTTAGTGGGAACC TGGTCAGGGACATCATCATGG 528 bp 
GAPDH CCATCACCATCTTCCAGGAGCG AGAGATGATGACCCTTTTGGC 149 bp 
 
Table 2-2. Thermal cycler conditions for standard PCR. 
Step Temperature Time 













Final extension 72°C 5 minutes 








LNCaP or PC3 cells were seeded in 6-well dishes and treated with adenovirus as 
outlined above. At 72 hours post infection, cells were washed once with 1X ice cold 
PBS. The cells were then harvested by adding a solution of 300 μL M-PER Mammalian 
Protein Extraction Reagent (Thermo Fisher Scientific) and 3 μL of HALT Protease 
Inhibitor Cocktail (Thermo Fisher Scientific) to each well and gently rocking the plate for 
5 minutes at room temperature. After incubation, the cell lysate was scraped out of each 
well, transferred to a sterile 1.5 mL microcentrifuge tubes, and centrifuged at 14,000 x g 
for 7 minutes at 4°C to pellet cell debris. The supernatant was collected and transferred 
to new, labeled microcentrifuge tubes. Lysate was stored at -20°C until further use. 
 
Western Blot 
SDS-PAGE was performed using the XCell SureLock Mini Cell (Invitrogen) 
according to the NuPAGE Novex Bis-Tris Protocol (Invitrogen). Protein concentration in 
lysate was normalized using the Bio-Rad Protein Assay Kit II (Bio-Rad). Samples were 
prepared for a total volume of 25 μL using 10 μg of protein, 6.25 μL of 4X NuPAGE 
sample buffer, 2.5 μL of 10X NuPAGE reducing agent (Thermo Fisher Scientific), and 
DI H2O. Samples were heated at 70°C for 10 minutes and immediately electrophoresed 
in a 4-12% Bis-Tris SDS-PAGE gel (Invitrogen) at 200 V for 45 minutes. Proteins were 
transferred to a PVDF membrane using the XCell II Blot Module run at 125 mA for 90 
minutes. Membranes were blocked on a plate shaker in a 5% Blotto/1X TBS-T (tris-
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buffered saline + Tween-20) solution at room temperature for 60 minutes followed by an 
overnight incubation on a plate shaker at 4°C in the appropriate primary antibody 
solution diluted in 5% Blotto (Table 2-3). The next day, membranes were washed three 
times with TBS-T at 5 minutes per wash on a shaker at room temperature. Appropriate 
HRP-conjugated secondary antibody dilutions were prepared in 1X TBS-T. Membranes 
were incubated with the secondary antibody dilutions for 60 minutes at room 
temperature with gentle shaking (Table 2-4). After incubation, membranes were washed 
three times at 5 minutes per wash in TBS-T followed by development using the Clarity 
Western ECL Substrate (Bio-Rad) according to manufacturer’s protocol. The 
immunoblots were visualized using the Bio-Rad ChemiDoc XRS+ machine with Image 




Table 2-3. Primary antibodies used in Western Blots 
Protein Target Animal of origin Brand Dilution 
DAX-1 Mouse monoclonal Active Motif 
(Cat # 39983) 
1:1000 
 
ERα Rabbit monoclonal MilliporeSigma 
(Cat # 04-820) 
1:1000 
 
ERβ Rabbit monoclonal MilliporeSigma 
(Cat # 04-842) 
1:1000 
 
GAPDH Rabbit monoclonal Cell Signaling 
Technology 




Table 2-4. Secondary antibodies used in Western Blots 
Probing against Animal of origin Brand Dilution 
HRP goat anti-mouse 
IgG 
Goat BD Pharmigen 
(Cat # 554002) 
1:1000 
 
HRP goat anti-rabbit 
IgG 
Goat GeneTex 
(Cat # GTX213110-01) 
1:1000 (for ERα and 
ERβ) 
1:2000 (for GAPDH) 
HRP goat anti-biotin 
(for biotinylated 
protein ladder) 
Goat Cell Signaling 
Technology 







Cells were plated in a 6-well dish with sterilized No. 1.5 22x22mm Corning cover 
glasses (Sigma Aldrich) that were previously incubated with FBS overnight. Treatments 
occurred in duplicate on each plate. Following 72-hour treatments with the appropriate 
adenovirus, cells were washed 3x with 1X PBS for 5 minutes per wash on a shaker. The 
cells were fixed in a 4% paraformaldehyde solution at 37°C for 20 minutes at room 
temperature. Following three 1X PBS washes, cells were permeabilized using 0.1% 
Triton X-100 in 1X PBS for 15 minutes at room temperature. Following three washes of 
10 minutes each, cells were further fixed and permeablized for 30 minutes using an ice-
cold 1:1 methanol:acetone solution. Following this final fixation and permeabilization 
step, cells were washed three times with 1X PBS and blocked for 1 hour at 37°C using 
a solution of 2% bovine serum albumin in 1X PBS. Primary antibodies probing for either 
DAX-1 and ERa or DAX-1 and ERβ were diluted in antibody dilution buffer (1% BSA, 
0.5% Tween-20, 1X PBS) (Table 2-5). Primary antibody dilutions were added to one set 
of untreated, LacZ adenovirus treated, and DAX-1 adenovirus treated cells. The other 
set, dubbed “secondary antibody only controls”, received antibody dilution buffer only. 
The cells were incubated for 1 hour at 37°C in a humidified chamber. After primary 
antibody incubation, three PBS washes occurred. Secondary antibodies with conjugated 
fluorophores were diluted in antibody dilution buffer and added to all cover slips (Table 
2-5). The cover slips were incubated in the dark for 30 minutes at 37°C in a humidified 
chamber. Following this incubation step, cells were washed three times with PBS with 
precaution taken to minimize the exposure to light. The cells were mounted onto 1 mm 
microscope slides using ProLong Diamond Antifade Mountant (Thermo Fisher 
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Scientific) and allowed to dry for a 24 hours in the dark before being sealed with nail 
polish. Slides were imaged using Zeiss A1 AxioObserver fluorescence microscope (Carl 
Zeiss Microscopy, LLC, Thornwood, NY) with ZEN Black software. Images were 
processed using ZEN Blue software and ImageJ software (National Institute of Health; 
Bethesda, MD).  
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Table 2-5. Protein targets and corresponding primary and secondary antibodies 
used in immunofluorescence microscopy experiments 
Protein Target Primary antibody Secondary antibody 
DAX-1 Active Motif 




(Cat # A-11004) 
Alexa Fluor 568 goat anti-mouse IgG 
Dilution 1:250 
ERα Abcam 




(Cat # A-11034) 
Alexa Fluor 488 goat anti-rabbit IgG 
Dilution 1:100 
ERβ Abcam 
(Cat # 3576) 
rabbit anti-ERβ 
Dilution 1:100  
ThermoFisher 
(Cat # A-11034) 







Prostate tumor cells express NHR genes 
Before the co-localization of DAX-1 and both ERs could be determined, it was 
important to first evaluate gene expression followed by protein expression of these 
NHRs in prostate tumor cell lines, LNCaP and PC3. LNCaP cells are still hormone-
naïve meaning they respond to the androgen-deprivation and stop proliferating in the 
absence of androgens. PC3 cells are aggressive CRPC cells that continue to proliferate 
despite the absence of androgens [84]. LNCaP cells and PC3 cells have differential 
gene and protein expression, thus it was necessary to investigate the presence of 
mRNA and protein expression of DAX-1, ERα, and ERβ within these cell lines. The 
expression of the GAPDH gene and GAPDH protein were used as positive controls for 
both mRNA and protein assays since it is stably expressed in mammalian cells. ERα 
and ERβ were also evaluated in the presence of over-expressed DAX-1 in order to 
assess whether increased levels of DAX-1 regulate gene or protein expression of ERs.  
To evaluate mRNA expression, cells were treated with virus accordingly and then 
harvested for mRNA. The mRNA was reversed transcribed into cDNA and cDNA was 
evaluated via RT-PCR for the presence of the NR0B1, ESR1, ESR2, and GAPDH 
genes. The NR0B1 gene codes for DAX-1 while ESR1 and ESR2 code for ERα and 
ERβ, respectively. PCR results indicated LNCaP cells constitutively express the NR0B1 
gene at detectable levels with no differences between mock-treated and untreated cells. 
Results also indicated that cells were permissible to infection with the DAX-1 adenovirus 
since NR0B1 had stronger expression when the LNCaP cells were exposed to the virus, 
meaning the DAX-1 adenovirus was successful in increasing levels of NR0B1 
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expression in LNCaP cells. LNCaP cells were observed to express the ESR1 and ESR2 
genes at low levels. Up-regulation of NR0B1 did not change the expression of the 
genes compared to untreated and mock-treated cells. GAPDH remained consistent 
across all treatments (Figure 2-1).  
PCR results indicate PC3 cells normally express NR0B1 in low quantities, though 
infection with DAX-1 adenovirus indeed caused an up-regulation of NR0B1 production. 
Furthermore, results suggested that no ERα was present in these cells due to a lack of 
signal of the ESR1 gene. However, ESR2 was detected in all cells despite treatment 
differences. ESR2 was not up-regulated when cells were infected with either DAX-1 
adenovirus or LacZ adenovirus. GAPDH remained consistent across all treatments 
(Figure 2-1). Overall, results indicate prostate cancer cell lines do express genes for 






Figure 2-1. Prostate cancer cell lines express NHR genes. RNA harvested from untreated, 
LacZ adenovirus treated, or DAX-1 adenovirus treated cells was reverse-transcribed to cDNA 
and analyzed for NR0B1, ESR1, and ESR2 expression. Results indicate hormone-naïve 
LNCaP cells expressed gene transcripts for the NHRs and higher levels of NR0B1 did not 
affect expression of ESR1 or ESR2. CRPC PC3 cells expressed NR0B1 at low levels though 
gene expression was increased following treatment with DAX-1 adenovirus. PC3 cells did not 
express ESR1 but consistently expressed ESR2, regardless of treatment. GAPDH was used 
as a positive control and was consistently expressed across all cell types and treatments.  
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DAX-1 co-localizes with ERα and ERβ within PCa cell lines 
Following the detection of the NR0B1, ESR1, and ESR2 genes, respective 
protein expression was determined in LNCaP and PC3 cells. The goal of these 
experiments was to verify protein expression matched mRNA expression suggested in 
the PCR experiments. Cells were untreated, LacZ adenovirus treated, or treated with 
DAX-1 adenovirus for 72 hours after which lysates were collected. Proteins were 
separated via SDS-PAGE and immunoblotted using antibodies specifically against 
DAX-1, ERα, and ERβ. GAPDH was used as a positive loading control. Surprisingly, the 
western blot results partially contradicted the PCR results. The western blots suggested 
that in LNCaP cells, there is very little to almost no expression of DAX-1 unless the cells 
are treated with DAX-1 adenovirus. This result contrasted the expected result (based on 
the PCR assays) that DAX-1 protein would be more detectable in the untreated and 
mock-treated samples. In agreement with the PCR results, LNCaP cells expressed 
similar levels of ERα and ERβ, regardless of the overexpression of DAX-1. GAPDH was 
consistent across all cell treatments (Figure 2-2). Protein detection in PC3 lysates was 
minimal, barring GAPDH protein detection. A band around 50 kDa corresponding to 
DAX-1 was faintly observed only in the cells treated with DAX-1 adenovirus. There was 
no detectable DAX-1 protein in the untreated or LacZ adenovirus treated samples which 
was to be expected based on the minimal expression of NR0B1 from the PCR results. 
No ERα signal was observed in any PC3 samples which corresponded to the PCR 
results of ESR1. ERβ was faintly detected in across all samples, although higher 
expression was expected (Lau 2000). GAPDH was equally expressed across all cell 
treatments (Figure 2-2). While these results were an important first step in determining 
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DAX-1, ERα, and ERb expression in PCa cell lines, they were inconsistent with the 
earlier PCR results suggesting the need for resolution. Published studies have noted 
discrepancies between PCR and western blots and suggest differing rates of mRNA 
translation in cell lines or lack of protein stability in certain cell lines are to blame [85-
86]. Perhaps ERβ is regulated at the protein level in PCa cell lines which is why this 






Figure 2-2. Prostate cancer cell lines express NHR proteins. Cells were untreated, LacZ 
adenovirus treated, or DAX-1 adenovirus treated for 72 hours after which lysates were 
collected. Protein detection occurred by immunoblotting using antibodies specifically against 
DAX-1, ERα, and ERβ. GAPDH acted as a loading control.  
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Immunofluorescence microscopy (IF microscopy) was performed as an 
alternative way of detecting proteins as well as a means of determining the localization 
of specific NHRs within PCa cell lines. LNCaP or PC3 cells were grown on coverslips 
and were uninfected or treated with either LacZ adenovirus or DAX-1 adenovirus for 48-
72 hours. After treatment, cells were fixed, permeabilized, and probed for DAX-1 and 
either ERα or ERβ. DAX-1 was stained using Alexa Fluor 568 (red fluorescence) while 
ER was stained using Alexa Fluor 488 (green fluorescence). DAPI (blue fluorescence) 
was used to stain the nuclei of cells. In contrast to the gene expression and protein 
expression results, the IF microscopy results suggest DAX-1 and both ERs are 
expressed within both PCa cell lines. 
In untreated LNCaP cells, DAX-1 had low basal expression in the nuclei which 
was to be expected given the results from the earlier western blot experiments. As 
expected, when treated with DAX-1 adenovirus, the expression of DAX-1 was up-
regulated. DAX-1 was seen to be primarily localized to the nuclei of the cells and had 
even dispersal throughout the nuclei. LacZ adenovirus treated LNCaP cells did not differ 
from untreated cells indicating the infection of adenovirus did not interfere with DAX-1 
expression or localization (Figure 2-3). LNCaP cells also exhibited strong expression of 
both ERa and ERβ protein. Both ERs demonstrated a localization preference to the 
cytoplasm of the cells, though both ERs were seen in the nuclei of the cells as well 
(Figure 2-3). ERβ had less of a presence in the nuclei compared to ERα. Additionally, 
ERβ had a distinct punctate dispersal pattern in the cytoplasm compared to ERα 
suggesting that ERβ was sequestered specific locations in the cell more so than its 
counterpart (Figure 2-3B). When captured images were merged (along with the DAPI 
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images for nuclei reference), DAX-1 and both ERs indeed co-localized partially in the 
cytoplasm but mostly in the nuclei of the LNCaP cells. This is the first documentation of 
this observation. 
The localization pattern of DAX-1 in LNCaP cells was observed to be similar in 
PC3 cells (Figure 2-4). Again, DAX-1 primarily localized to the nuclei of PC3 cells, 
though there was residual expression in the cytoplasm of the cells. When DAX-1 was 
overexpressed via adenovirus, it was apparent DAX-1 preferentially localized to the 
nuclear compartment of the cells. In contrast to the LNCaP cells, PC3 cells exhibited 
fairly equal ERα expression across the cells (Figure 2-4A). While in LNCaP cells, ERα 
showed a clear affinity for cytoplasmic localization, in PC3 cells ERα only exhibited a 
slight affinity for the cytoplasm over the nucleus. ERβ expression in PC3 cells was 
similar to expression in LNCaP cells. Once again, ERβ had less of a presence in the 
nuclei compared to ERα. It also had more punctate dispersal in the cytoplasm 
compared to ERα. In contrast to ERβ in LNCaP cells, an increased amount of ERβ was 
present in the nuclei of PC3 cells (Figure 2-4B). When images were merged, DAX-1 and 
both ERs again co-localized partially in the cytoplasm but mostly in the nuclei of the 
PC3 cells. The results from these IF microscopy experiments are the first evidence of 















Figure 2-3. DAX-1 and ERs co-localize in the nuclei of LNCaP cells. Immunofluorescence 
microscopy was performed on LNCaP cells to detect the localization of DAX-1 and ERα (A), 
and DAX-1 and ERβ. DAPI was used to stain the nuclei of cells. A) ERα was localized primarily 
to cytoplasm of the cells, though it was detected in the nuclei of cells. DAX-1 was localized to 
the nuclei of cells. DAX-1 and ERα were co-localized in the nuclei. B) ERβ was localized 
primarily to cytoplasm of the cells but was also detected in the nuclei. DAX-1 was localized to 







Figure 2-4. DAX-1 and ERs co-localize in the nuclei of PC3 cells. Immunofluorescence 
microscopy was performed on PC3 cells to detect the localization of DAX-1 and ERα (A), and 
DAX-1 and ERβ (B). DAPI was used to stain the nuclei of cells. A) ERα was dispersed almost 
evenly throughout the cells, though it did show slight preference for the cytoplasm of cells. 
DAX-1 was localized to the nuclei of cells. DAX-1 and ERα were co-localized in the nuclei. B) 
ERβ was localized primarily to cytoplasm of the cells but was also detected in the nuclei. DAX-
1 was localized to the nuclei of cells. DAX-1 and ERβ were co-localized in the nuclei. Scale 




This study explored the expression and localization of the NHRs, DAX-1, ERα, 
and ERβ within human PCa cell lines. Two commonly used PCa cell lines were chosen 
based differential response to ADT. The first cell line, LNCaP, is known to express AR 
in the cytoplasm of cells [87]. The cell line demonstrates a decrease in proliferation 
when androgens are removed making it a good model for hormone-naïve PCa. The 
second cell line, PC3, has also been shown to express AR [88], but does not stop 
proliferating despite a lack of androgens in the environment. This cell line is widely 
observed to be an example of CRPC, which is nearly impossible to treat. Because the 
two PCa cell lines behave differently in response to hormone treatments, it is important 
to characterize the statuses of NHRs and later, the mechanisms of NHRs since there 
are likely differences between hormone-naïve and castration-resistant PCa tumors 
which could be exploited for drug therapeutics. 
This study focused the on the localization of ERs since there is controversy 
around ER presence and mechanisms within PCa tumors. Additionally, we focused on 
the localization of DAX-1, an orphan NHR that is known to bind to ERs and AR and 
whose up-regulation is correlated with a more favorable prognosis of PCa [69]. PCR 
was initially used to detect mRNA transcripts corresponding to each NHR in LNCaP and 
PC3 cells. Results indicated LNCaP cells expressed mRNA transcripts pertaining to the 
DAX-1, ERα, and ERβ genes. Despite clear DAX-1 up-regulation via adenovirus, the 
levels of ERα and ERβ mRNA transcripts qualitatively remained similar to levels of 
mRNA in untreated cells suggesting that under these conditions, DAX-1 does not 
induce nor suppress transcription of estrogen receptors. This is unexpected because 
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unpublished findings from our lab suggest DAX-1 down-regulates AR expression via an 
AR negative feedback loop. The study suggests activated AR increases transcription of 
the NR0B1 gene and once the mRNA transcripts are translated, the DAX-1 protein acts 
as co-repressor to AR. Our results with ER do not indicate DAX-1 and ER are involved 
in a feedback loop. 
 PCR results in PC3 cells support the observations seen in the LNCaP cells. The 
untreated and mock-treated PC3 cells expressed low levels of DAX-1 mRNA while the 
DAX-1 adenovirus treated cells had higher levels of DAX-1 mRNA. Despite an up-
regulation in DAX-1, PC3 cells did not qualitatively exhibit an up-regulation in ERβ 
mRNA. However, these results would be better supported with quantitative data via 
quantitative PCR (qPCR) reactions. Curiously, and in contrast to previous studies, no 
ERα mRNA was detected within PC3 cells [70, 89]. Possible explanations for this 
discrepancy include the use of different PCR primers or differences in PCR conditions 
that do not detect low expression levels. 
 Because of the discrepancy in our PCR results compared to previous studies, 
protein detection methods of immunoblotting and IF were used to confirm the results 
and to add to the general understanding in terms of expression and localization patterns 
of DAX-1, ERα, and ERβ within the chosen PCa cell lines. Immunoblotting results 
suggested LNCaP cells expressed all three NHRs while PC3 cells did not express ERα, 
and only slightly expressed DAX-1 and ERβ. Interestingly, the IF microscopy results in 
PC3 cells contradicted our immunoblotting results. The results demonstrated the 
presence of DAX-1, ERα and ERβ proteins within the cytoplasm and the nuclei of the 
cells. These results are relevant in terms of the known literature because there are 
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conflicting results of ERa protein expression within PC3 cells. One study detected ERα 
protein via immunoblotting while another study used the same technique but did not find 
evidence of ERα expression [89-90]. It is worth noting numerous studies have 
suggested ERα is up-regulated in prostate cancer tissues as the cancer becomes 
progressively worse [74-76]. Therefore, the detection of ERα expression in PC3 cells, a 
cell line derived from an aggressive form of PCa, aligns with these previously published 
studies.  
It is less clear what the role of ERβ is in PCa.  Results demonstrate ERβ 
expression in the cytoplasm and partially in the nuclei of both LNCaP and PC3 cells. 
While there are published studies that have demonstrated the presence of ERβ within 
these cells [89-90], other studies have demonstrated the loss of ERβ in prostatic tissue 
as PCa progresses [47; 91-92]. Therefore, it is interesting to note sustained ERβ 
expression in the CRPC cell line, PC3. Recent studies have suggested perhaps ERβ is 
actually sustained in CRPC tissues and isoforms of ERβ have an impact on cell 
physiology and behavior [93-95]. In light of these studies, our results support the 
observations that ERβ expression does not disappear as PCa progresses and in fact, is 
sustained even in CRPC cell lines.  
While ER expression and localization have been extensively profiled in PCa cell 
lines, few studies have focused on DAX-1 expression and localization in PCa cells. This 
study found that DAX-1 was mainly localized to the nuclei of hormone-naïve and CRPC 
cells, though the protein can also be detected in low levels in the cytoplasm. These 
results echo the results of other studies that found DAX-1 localized mainly to the nuclei 
of other types of cancer cells and tissues [96-97]. More importantly, this study 
Vijayraghavan, Meghana 
 50 
suggested the novel finding that DAX-1 is co-localized with both ERα and ERβ 
regardless of the severity of PCa. The implication of this finding is that because DAX-1 
is expressed in the same place at the same time as ERs, the orphan NHR can 
potentially bind ER in vivo and mediate the negative effects of ER signaling with PCa 
cell lines. These findings indicate there is the potential to develop alternative therapies 
for PCa that function to increase the expression of DAX-1 as a means of inhibiting cell 







Validation of DAX-1 and ER protein interaction 
Introduction 
In order to evaluate the effects of DAX-1 coupled with ER in PCa, it was 
necessary to elucidate the mechanisms behind these NHR interactions. It has 
previously been determined that the ability of DAX-1 to directly bind a variety of 
transcription factors is through the LXXLL motifs present in its N-terminus of DAX-1. Of 
particular interest are those transcription factors in the same family as ER. DAX-1 has 
demonstrated binding affinity for: ER within COS-7 cells [60], AR within LNCaP and 
COS-7 cells [61-62], progesterone receptor within T47D breast cancer cells [62], 
glucocorticoid receptor within COS-1 cells and A549 lung cancer cells [98], and 
estrogen receptor-related receptor gamma within MCF-7 breast cancer cells [99]. In 
these reported studies, DAX-1 was shown to act as a co-repressor by binding to the 
AF2 sites in the various nuclear receptors. Typically, DAX-1 was overexpressed via 
transient transfection of a DAX-1 plasmid in order to increase the amount of DAX-1 
present in these assays.  Different techniques, including GST (glutathione-S-
transferase) pull-down assays and co-immunoprecipitation assays (Co-IPs), were 
employed to determine whether a physical interaction of DAX-1 and the nuclear 
receptor of interest existed. Though all of the aforementioned studies are over a decade 
old, the techniques used are still relevant and still the gold standard to detect protein-
protein interactions within mammalian cell models. 
For this study, GST pull-down assays and co-IPs were used in order to evaluate 
DAX-1 and ERα interaction within LNCaP cells. To date, data by Zhang et. al 
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demonstrating the interaction between DAX-1 and ERα in addition to DAX-1 and ERβ 
within COS-7 cells remains the only published work to have looked at the DAX-1/ER 
interaction. Therefore, this current study will contribute to our understanding of NHR 
interactions within cancer cells.  
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Materials and Methods 
GST Pull-down Assays  
 Competent BL21 (DE3) E.coli cells (New England Biolabs; Ipswich, MA) were 
thawed on ice in 50 μL aliquots and transformed with 100 ng of either GST-EGFP 
control vector (henceforth referred to as GST-only) or custom-made GST-DAX-1 vector 
expressing the T7 promoter (Genecopoeia; Rockville, MD) according to the NEB 
protocol. Transformed BL21 cells was plated at 25 μL on separate LB + Ampicillin (100 
ug/mL ampicillin) plates and grown overnight at 37°C. The next day, individual colonies 
were picked and added to individual starter cultures of 5 mL of LB-Ampicillin broth 
(1:1000 ampicillin) and grown overnight at 37°C with shaking. The following day, 500 
mL of LB-Ampicillin broth was inoculated with the 5 mL starter culture and grown at 
37°C in a shaker until an optical density of at least 0.500 was reached. The cultures 
were then induced with isopropyl β-D-1-thiogalactopyranoside (IPTG) for a final 
concentration of 0.2 mM IPTG. Induced cultures were grown for an additional 4 hours at 
30°C with shaking. Cultures were then aliquoted into 50 mL conical vials and 
centrifuged at twice at 3500 x g for 20 minutes at 4°C to pellet the cells. The pellets 
were then stored at -20°C for at least 60 minutes prior to lysis. 
 In order to lyse bacterial cells and purify either GST-only protein or GST-DAX-1 
protein, pellets were thawed for 10 minutes on ice, centrifuged at 7500 x g for 10 
minutes at 4°C to get rid of any residual supernatant and to concentrate the pellet, 
resuspended in 2 mL of 1X PBS-Lysis (PBS-L) buffer (1X PBS, 1X HALT protease 
inhibitor, 1% Triton X-100, 1 mM EDTA, 1 mg/mL lysozyme), and then sonicated to 
further disrupt the membranes. Lysate was then centrifuged at 10,000 x g for 10 
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minutes at 4°C. Supernatant was transferred 1.5 mL ftubes and either used immediately 
or stored at -20°C. 
 To immobilize the bait protein, a 50% slurry of Pierce Glutathione Agarose beads 
(Thermo Fisher Scientific) was prepared in a solution of 1X PBS with 1X HALT protease 
inhibitor. A solution of 50 μL 50% slurry and either 300 μL GST-only or GST-DAX-1 was 
incubated overnight at 4°C in a rotator to bind the protein to the agarose beads. After 
the pre-bind step, the beads were centrifuged at 5000 x g for 2 minutes at 4°C and the 
supernatant was decanted. The beads were then resuspended in ~50 μg of untreated 
LNCaP lysate. If E2 treatment was appropriate, E2 was added for a final concentration of 
1 μM. Suspensions were incubated for 4 hours at 4°C in a rotator. After binding, the 
beads were centrifuge at 5000 x g for 2 minutes at 4°C. Supernatant was discarded at 
the beads were washed 5 times with 500 uL 1X PBS. In between washes, beads were 
centrifuged at 12000 x g for 15 minutes at room temperature and supernatant decanted 
via pipetting. After the final wash, the beads were prepared for protein separation via 
SDS-PAGE. Each sample was resuspended in 32.5 μL 1X PBS, 12.5 μL of 4X NuPAGE 
sample buffer, and 5.0 μL of 10X NuPAGE reducing agent (Thermo Fisher Scientific). 
Samples were then heated at 70°C for 10 minutes to elute the proteins off the beads 
then centrifuged at 10,000 x g for 2 minutes at room temperature. The supernatant was 
loaded and electrophoresed and transferred to a PVDF as described in the Western 
Blot methods in chapter 2. DAX-1 and ERα were probed for using the primary and 






Co-immunoprecipitation assays (co-IPs) were performed using the Dynabeads 
Co-Immunoprecipitation kit (Invitrogen) according to the manufacturer’s protocol. Briefly, 
DAX-1 antibody (Active Motif) was covalently coupled to the Dynabeads M-270 Epoxy 
beads at a ratio of 6 ug antibody/mg beads. The bead-antibody complex was 
assembled so as to use 1.5 mg/ co-IP reaction. Antibody coupling procedure followed 
the manufacturer’s protocol. Coated beads were used immediately or were stored at 
4°C for no more than one week following antibody coupling.  
Two confluent 15 cm dishes of LNCaP cells were seeded and left untreated or 
treated with LacZ adenovirus for 72 hours. After treatment, cells were washed twice with 
1X PBS and harvested using 0.25% Trypsin-EDTA. Cells were transferred to 15 mL 
conical vials, centrifuged at 300 x g for 5 minutes, washed once with 1X PBS, and 
centrifuged again at 300 x g. Supernatant was decanted and cell pellets were gently 
suspended in Dynabeads Extraction Buffer A supplemented with 100 mM NaCl, and 1X 
HALT protease inhibitor according to the manufacturer’s recommendation. Lysates were 
placed on ice for 15 minutes then centrifuged at 2600 x g for 5 minutes at room 
temperature to separate large cell debris. The supernatants were transferred to 1.5 mL 
microcentrifuge tubes and immediately used in co-IP reactions. In each co-IP reaction, 
1.5 mg of antibody-coupled beads was added to fresh lysate and incubated for 45 
minutes on a rotator at 4°C. After incubation, beads were concentrated in the tube using 
a magnet. The supernatant was transferred to a 1.5 mL microcentrifuge tube labeled 
“Flow-through.” Beads were washed three times with 200 uL extraction buffer. After 
every wash, the beads were collected using a magnet and the supernatant was 
Vijayraghavan, Meghana 
 56 
transferred to a 1.5 mL microcentrifuge tube labeled “3X washes”. The co-IP reactions 
were then washed one final time using the Dynabeads “last wash buffer” supplemented 
with 0.02% Tween-20 and beads were collected and supernatant was discarded. The 
beads were suspended in 60 μL of the Dynabeads EB buffer and incubated on a rotator 
for 15 minutes at room temperature. The beads were collected using a magnet and the 
supernatants were transferred to clean 1.5 mL microcentrifuge tubes labeled “eluted 
protein.” The tubes containing the beads were labeled “beads only” and contents were 
directly prepared for analysis via SDS-PAGE. Co-IPs were analyzed via western blot 
using conditions outlined in chapter 2. Samples were prepared using 16.25 μL protein 
sample, 6.25 μL 4X NuPAGE sample buffer, and 2.5 μL 10X NuPAGE reducing agent. 
Immunoblots were probed using antibodies against ERα, AR, or DAX-1 (Table 3-1, 





Table 3-1. Primary antibodies used for western blot analysis of co-IP reactions 
Protein Target Animal of origin Brand Dilution 
DAX-1 Mouse monoclonal Active Motif 
(Cat # 39983) 
1:1000 
 
ERα Rabbit monoclonal MilliporeSigma 
(Cat # 04-820) 
1:1000 
 
AR Rabbit polyclonal GeneTex 




Table 3-2. Secondary antibodies used for western blot analysis of co-IP reactions 
Probing against Animal of origin Brand Dilution 
HRP goat anti-mouse 
IgG 
Goat BD Pharmigen 
(Cat # 554002) 
1:1000 
 
HRP goat anti-rabbit 
IgG 
Goat GeneTex 
(Cat # GTX213110-01) 






Determination of DAX-1 and ER interaction  
This study used two methods, GST pull-down assays and co-IPs, to investigate 
whether a direct protein-protein interaction between DAX-1 and ERα exists within 
LNCaP cells. Before all interactions in the desired cell lines were explored, protocols 
were optimized using one cell line (LNCaPs) and primarily focused on the DAX-1/ERα 
interaction. For the GST pull-down assays, purified GST-only protein or GST-DAX-1 
protein was bound to glutathione-agarose beads and incubated with LNCaP lysate that 
was either untreated or treated with 1 μM E2. The complex was then isolated, separated 
via SDS-PAGE, transferred to a PVDF membrane and probed for DAX-1 and ERα. 
When probing for DAX-1, bands approximately 52 kDa were detected in every lane 
except for the GST-only lane (Figure 3-1). When comparing GST-only lanes with 
LNCaP lysate to GST-DAX-1 lanes with LNCaP lysate, bands were detected that 
migrated at a lower molecular weight than the bands detected in the GST-DAX-1 lanes. 
It was also observed that there were two bands in the GST-DAX-1 + lysate lanes 
compared to the GST-only + lysate lanes. The lower bands were approximately the 
same molecular weight as the bands in the GST-only lanes (Figure 3-1, lower arrow). 
We speculate that the bands seen at the lower size in both the GST-only and the GST-
DAX-1 lanes were residual DAX-1 protein from the lysate indicating more stringent 
washes were needed after the beads and complexes were pulled down. This conclusion 
is supported by the lack of band in the GST-only lane, indicating that there was no 




When probing for ERα, bands around 66 kDa were detected in every lane 
exposed to LNCaP lysate (Figure 3-1). Interestingly, the lanes with GST-DAX-1 had 
faint bands of ERα when compared to the GST-only lanes, regardless of ERα activation 
via E2. Even more curious, GST-DAX-1 incubated with LNCaP lysate produced a fainter 
band compared to GST-DAX-1 with lysate and E2 treatment. While these results seem 
to indicate there is a difference in ERα to DAX-1 in the presence of hormone, further 
optimization of the GST binding experiments is needed to provide conclusive evidence 






Figure 3-1. GST pull-down assays using LNCaP lysate. GST-only and GST-DAX-1 proteins 
were purified and bound to glutathione agarose beads. The beads were exposed to either 
LNCaP lysate alone or LNCaP lysate and 1uM E2 then pulled out of solution, washed, and 
proteins dissociated off the beads via heat. The dissociated proteins were separated via SDS-
PAGE and probed for DAX-1 and ERα. Results indicate GST-DAX-1 was purified properly as 
bands against DAX-1 protein were expressed around the predicted molecular weight of 78 kDa 
(GST = 26 kDa, DAX-1 = 52 kDa).  Bands around 58 kDa were thought to be residual DAX-1 




In addition to the GST pull-down assays, co-immunoprecipitation experiments 
aimed at examining the interaction of DAX-1 with ERα were performed. The anti-DAX-1 
antibody was covalently coupled to magnetic beads and incubated with freshly lysed 
LNCaP lysate that was either untreated or treated with LacZ adenovirus. The goal of 
these experiments was to examine endogenous protein-protein interactions, therefore 
there was no exogenous DAX-1 expression via adenovirus or upregulation of ER via E2 
treatment. Lysate was collected from four points in the assay: the flow-through after the 
beads had been exposed to LNCaP lysate, the wash buffer used to rinse the exposed 
beads, the beads themselves which were re-suspended in SDS-PAGE sample buffer, 
and the eluted protein complexes. Through these experiments, it was discovered that 
ERα was only expressed in the flow-through lysate (Figure 3-2).  Since previous 
experiments suggested DAX-1 physically interacted with AR in LNCaP cells, the 
immunoblot was probed with an AR antibody. Results show faint bands (marked by 
arrows) in the eluted protein lanes of both untreated and LacZ adenovirus treated 







Figure 3-2. Co-immunoprecipitation assays using anti-DAX-1 coupled beads and LNCaP 
lysate. DAX-1 antibody was covalently coupled to magnetic beads. The beads were exposed 
to either untreated LNCaP lysate or LacZ adenovirus treated LNCaP lysate. At various points 
in the assay, samples were collected and analyzed via SDS-PAGE and immunoblot.  ERα was 
only detected in the flow-through after the covalently coupled anti-DAX-1 beads were exposed 
to lysate. No ERα was detected in any other lane. AR, a known binding partner of DAX-1, was 
detected in both the flow-through and in the purified, eluted protein sample (indicated by the 
arrows at roughly 110 kDa) demonstrating DAX-1 had the ability to bind another NHR under 




This portion of thesis work aimed to clarify the protein-protein interaction of DAX-
1 and ER within PCa cell lines. Previous research by Zhang et al. indicated DAX-1 
utilizes the repeating LXXLL motifs to bind to the AF2 domain of ERα and ERβ. This 
complex was determined to exist using three methods: GST pull-down assays, co-IPs, 
and yeast two-hybrid assays. The Zhang study then went on to characterize the 
functional effects of DAX-1 binding to ER and found that DAX-1 repressed 
transcriptional activity of ERα and ERβ in a dose-dependent manner [60]. This thesis 
work aimed to determine whether this interaction and functional effect was present 
within PCa cell lines. Specifically, these studies focused on detecting an interaction 
between DAX-1 and ERα in LNCaP cells. 
Initially, GST pull-down assays were performed and results indicated that GST-
only and GST-DAX-1 proteins were successfully purified. However, the results from 
these assays were not conclusive due to the presence of DAX-1 in samples, most likely 
due to low-stringency washes, suggesting that it is necessary to increase the number of 
stringent washes when performing the assay to minimize residual DAX-1 binding. When 
probing for ERα in the GST pull-down assays, higher ERα expression in the GST-only 
lanes compared to the GST-DAX-1 lanes was observed. This indicates that more 
stringent washes were needed in order to determine whether the GST-only beads were 
actually capturing the ERα or whether expression was just an artifact of non-specific 
binding. Interestingly, the results from the GST-DAX-1 construct indicate direct binding 
to ERα which increased upon exposure to E2.  These results support previous results 
(unpublished) from our research lab that demonstrate DAX-1 binds directly to ERα in 
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vitro. Further optimization of the GST pull-down experiments needs to be conducted 
before any conclusions can be drawn. 
As an alternative to the GST pull-down assays, co-IPs were used to evaluate the 
DAX-1/ER interaction within LNCaP lysate. The results from these experiments indicate 
DAX-1 does not bind with ERα. However, further optimization needs to be performed. 
When AR was used as a positive control for DAX-1 interaction, only a faint band was 
detected, but not what was expected given that other studies have found a moderate 
amount of AR interacting with DAX-1 [62]. In our case, the lysis buffer used to extract 
proteins from the LNCaP cells may have disrupted the protein-protein interactions, 
which hindered our ability to detect the interaction. Therefore, further optimization is 
required. One possible approach could be to overexpress DAX-1 and ERs either 
through transient transfection with expression plasmids for DAX-1, ERa and ERb 
through the use of adenovirus. While this approach doesn’t address endogenous 
protein-protein binding, it is still a viable way of detecting whether DAX-1 has the ability 
to bind ERs within PCa cell lines.  
Should future studies find that DAX-1 and ERs interact within PCa cell lines, 
functional assays determining the effect of DAX-1 on activated ER activity will have to 
be performed. Though the functions of ERs within PCa are still highly debated, it is 
expected that overexpressing DAX-1 will repress the transcriptional activity of the ERs 
causing PCa cells to halt in proliferation and metastasis. Therefore, this work was a 
necessary first step in determining whether DAX-1, ERα, and ERβ are viable 
therapeutic options for prostate cancer patients that remain without any other hormone-





The rise and progression of prostate cancer involves a complex network of 
biological processes and protein interactions that are mainly driven via the nuclear 
hormone receptor, androgen receptor. Thus, the most common targeted treatment for 
prostate cancers involves depleting the body of androgens so androgen receptor is 
never activated. However, this treatment, known as androgen-deprivation therapy, 
eventually fails and prostate cancer cells continue to proliferate and metastasize. 
Presently, there is no other viable option for hormonal treatment due to the lack of 
research involving other nuclear hormone receptors in the context of prostate cancer. 
Therefore, this thesis work aimed to elucidate the presence and location of three 
nuclear hormone receptors, DAX-1, ERα, and ERβ, within prostate cancer cells lines. 
Studies have demonstrated DAX-1 is present in prostatic tissues, but the level of 
DAX-1 protein in tissues is variable depending on the patient. DAX-1 is known to act as 
a co-repressor of other nuclear hormone receptors, but its relationships to ERs within 
prostate cancer cells has never been explored.  ERα is classified as an oncogenic 
protein that mediates proliferation, inflammation, and carcinogenesis of prostate cells. 
ERβ has a more controversial role within PCa with some studies demonstrating its anti-
oncogenic properties while other studies dispute earlier findings and suggest ERβ also 
mediates an increase in proliferation of castration-resistant prostate cancer cells. 
Because of the potential effects that these three NHRs have on prostatic 
carcinogenesis, the research conducted throughout this thesis aimed to clarify the 
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physical interactions between nuclear hormone receptors, ERα, ERβ and DAX-1, all of 
which have the potential to be therapeutic targets for new treatments of prostate cancer. 
 The first portion of this thesis work, as detailed in Chapter 2, identified gene and 
protein expression of DAX-1, ERα, and ERβ in two different PCa cell lines, an 
androgen-dependent line known as LNCaP and an androgen-resistant line known as 
PC3. Results of PCR experiments indicated that LNCaP cells expressed gene 
transcripts for all the NHRs. PC3 cells expressed the DAX-1 gene at low levels and also 
expressed the ERβ gene. This cell line had no detectable gene expression for ERα. 
When DAX-1 was over-expressed in both cell lines via adenovirus, the gene expression 
levels of ERα and ERβ did not change, suggesting that DAX-1 plays no role in 
regulating gene expression of both ERs. Once gene expression was evaluated, protein 
expression was analyzed via immunoblotting. Surprisingly, DAX-1 protein expression in 
LNCaP cells partially contradicted expected results indicated by PCR experiments as 
DAX-1 was only detected in samples that had been treated with adenovirus. This 
suggests that in LNCaP cells, DAX-1 may be regulated at the DNA or RNA level and not 
be translated into protein. However, in agreement with the PCR results, LNCaP cells did 
express both ERs and ER expression was not dependent on DAX-1 expression. 
Detection of NHR proteins in PC3 lysates was minimal, with one faint band detected 
when DAX-1 was overexpressed via adenovirus. ERβ was faintly detected across all 
conditions, but no ERα was detected. To further investigate the pattern of NHR 
expression in PCa cells, a second protein-detection technique was employed. Using 
immunofluorescence microscopy, it was determined that all three NHRs were 
expressed in both LNCaP and PC3 cells. These finding indicate that DAX-1 is able to 
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co-localize with ERα and ERβ within each cell line, regardless of cell line androgen 
sensitivity.  
The findings detailed in Chapter 2 were used to guide the work detailed in 
Chapter 3. In summary, the interaction of the various NHRs were explored via GST pull-
down assays and co-immunoprecipitation assays. Although two independent 
approaches were utilized, the results remain inconclusive. Future work will be focused 
on refining the co-IP assays and examining the functional effects of DAX-1 and ER 
binding. It is still strongly theorized that DAX-1 binds both ERα and ERβ within prostate 
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